Protestors Rally In New York Against EipPen Price Gouging Scandal
Timothy Lunceford Stevens holds an EpiPen during a protest against the price of EpiPens, Aug. 30, 2016 in New York City.  Drew Angerer—Getty Images

Investors Are Calling on Mylan’s Chairman and Director to Step Down

Jun 28, 2017

An investor group led by New York City's comptroller called for Mylan NV's (myl) Chairman Robert Coury and Director Wendy Cameron to step down, as part of a campaign against the firm's executive pay packages and high prices for an allergy treatment.

More than a third of the investors voting at the generic drugmaker's annual meeting last week cast votes against Coury, while over half voted against Cameron—who heads Mylan's compensation committee, a letter reviewed by Reuters shows.

"We believe Mylan's independent directors must act swiftly—or risk further erosion in shareowner confidence and value," the investors wrote in the letter to Mylan's independent directors.

"Mylan's share price is already down nearly 50% since its April 2015 peak and the company remains under legal, regulatory and public scrutiny for its EpiPen pricing practices," they added in the letter.

Mylan could not be immediately reached for comment.

The company has been grappling with a growing backlash from U.S. consumers over the price of its life-saving allergy treatment EpiPen after it shot up to more than $600 for a two-pack of the device from less than $100 in 2007.

While the sharp price spike spurred congressional, Justice Department and other government investigations, the shareholder campaign against Mylan's board picked up steam after Chairman Coury's nearly $100 million pay package was disclosed earlier this year.

For more on Mylan, watch Fortune's video:

The investor group, including New York City and State pension funds and the California teachers pension fund, have asked for Coury to forfeit most of the pay he received last year. It also urged Mylan to hire an independent chairman and reconstitute its board with a majority of independent directors.

The investors agitating against Mylan's board had a steep threshold to cross as more than two-thirds of the shares voted, as well as more than half of Mylan's outstanding shares, would have needed to be cast against the directors for them to lose.

Neil Dimick and Mark Parrish, directors on the company's compensation committee, had just under 50% of the shares voted cast against their re-election.

Investors also cast more than a quarter of the shares voted against Chief Executive Heather Bresch.

Mylan announced the vote totals from the meeting in a filing with regulators on Wednesday. The company had previously only said that all its directors had been re-elected.

More than 80% of the company's shares voted were cast against the company's 2016 executive pay packages. That vote was a non-binding, advisory measure.

New York City comptroller Scott Stringer, who oversees the city's pensions and is one of the leaders of the campaign against the drugmaker's board, said the board needed to act swiftly to restore investor confidence.

"This board's oversight failures have hurt investors, consumers and American taxpayers. We need to see change," Stringer said in a statement.

All products and services featured are based solely on editorial selection. FORTUNE may receive compensation for some links to products and services on this website.

Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions